MCL1 Monoklonaler Antikörper

• Featured Product
• KD/KO Validated

MCL1 Monoklonal Antikörper für FC (Intra)

Wirt / Isotyp

Maus / IgG2b

Getestete Reaktivität

human

Anwendung

FC (Intra)

Konjugation

CoraLite® Plus 647 Fluorescent Dye

CloneNo.

1E3C2

Kat-Nr. : CL647-66026

Synonyme

EAT, Mcl 1, Mcl 1l, Mcl 1s Delta TM, MCL1, mcl1/EAT, MCL1L, MCL1S, TM

---

Galerie der Validierungsdaten

• 

  FC experiment of HeLa using CL647-66026

  1X10^6 HeLa cells were intracellularly stained with 0.2 ug CoraLite® Plus 647 Anti-Human MCL1 (CL647-66026, Clone:1E3C2) (red), or 0.2 ug Control Antibody (blue). . Cells were fixed with 4% PFA .

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in FC: HeLa-Zellen

Empfohlene Verdünnung

Anwendung	Verdünnung
Sample-dependent, check data in validation data gallery

Produktinformation

CL647-66026 bindet in FC (Intra) MCL1 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Maus / IgG2b
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: MCL1 fusion protein Ag10609
• Vollständiger Name: myeloid cell leukemia sequence 1 (BCL2-related)
• Berechnetes Molekulargewicht: 350 aa, 37 kDa
• GenBank-Zugangsnummer: BC107735
• Gene symbol: MCL1
• Gene ID (NCBI): 4170
• Konjugation: CoraLite® Plus 647 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 654 nm / 674 nm
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: BS mit 50% Glyzerin, 0,05% Proclin300, 0,5% BSA, pH 7,3.
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target.